GFAP Antibody (CL2713) - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-44413

Submit a review

Product Datasheet / COA / SDS

View Available Formulations

Forumulation

Catalog #

BSA Free

NBP2-76477

Product Specifications
Scientific Data
Applications
Preparation & Storage
Background
Product Documents
Specific Notices

Key Product Details

Validated by

Knockout/Knockdown, Orthogonal Validation

Species Reactivity

Human, Mouse, Rat

Applications

Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG₁ Clone # CL2713

Format

Azide and BSA Free

Concentration

LYOPH mg/ml

View all GFAP Antibodies »

Product Specifications

Immunogen

This antibody was generated using a recombinant protein sequence of P14136, with the exact immunogen sequence remaining proprietary.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG₁

Scientific Data Images for GFAP Antibody (CL2713) - Azide and BSA Free

Immunohistochemistry-Paraffin: GFAP Antibody [NBP3-44413]

Analysis in human cerebral cortex and tonsil tissues using NBP3-44413 antibody. Corresponding GFAP RNA-seq data are presented for the same tissues.

Immunohistochemistry-Paraffin: GFAP Antibody [NBP3-44413]

Staining of human cerebral cortex shows strong cytoplasmic positivity in astrocytes.

Western Blot: GFAP Antibody [NBP3-44413]

Analysis in U-87MG ATCC cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-GFAP antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.

View 6 more images

Applications for GFAP Antibody (CL2713) - Azide and BSA Free

Application

Recommended Usage

Immunohistochemistry-Paraffin

1:5000 - 1:10000

Western Blot

1 ug/ml

Application Notes

For IHC-Paraffin, HIER pH 6 retrieval is recommended.

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Centrifuge the vial of lyophilized antibody at 12,000 x g for 20 seconds. Reconstitute by adding sterile, distilled water to achieve a final antibody concentration of 1mg/ml.

Formulation

Lyophilized from a 0.2 um filtered solution in PBS with Trehalose

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: GFAP

Glial fibrillary acidic protein (GFAP) is a class III intermediate filament protein that is largely expressed in astrocytes in addition to non-myelinating Schwann cells and glial cells (1,2). Other members of the type III intermediate filament family include desmin, peripherin, and vimentin (2-4). GFAP was first identified in the brains of multiple sclerosis patients (2). Human GFAP protein is 432 amino acids in length with a theoretical molecular weight of ~50 kDa (1,3). GFAP has at least 10 known isoforms, with the most prevalent and common in the brain being GFAP-alpha which is made of a head domain, a rod domain with four coils (1A, 1B, 2A, 2B) joined by linker regions, and a tail domain (1). GFAP is a marker of mature astrocytes, but is also expressed throughout development in both fetal and adult neural stem cells (2). While the exact function of GFAP is still elusive, it has been shown to play a role in cellular processes such as migration, mitosis, structural integrity, and signaling (2).

An increase in GFAP levels is often associated with neuroinflammation which results in the activation and proliferation of astroglia cell population (1,2). GFAP expression is also observed in brains of patients with neurodegenerative diseases including Alzheimer's and Parkinson's, epilepsy disorders, and brain injuries (1-4). Lesion sites associated with neurodegeneration can exhibit an array of gliosis characteristics from glial scarring with reduced astrocyte proliferation to activated, GFAP-positive astrocytes surrounding amyloid plaques (2). Furthermore, the GFAP gene is a target of single nucleotide polymorphisms in the coding region, considered a gain-of-function mutation, characterized by astrocytic inclusions, termed Rosenthal fibers, resulting in Alexander Disease (1-4). GFAP is also a center of many post-translational modifications, such as phosphorylation, which can alter various aspects of filament assembly (1,4).

References

1. Yang, Z., & Wang, K. K. (2015). Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends in Neurosciences. https://doi.org/10.1016/j.tins.2015.04.003

2. Hol, E. M., & Capetanaki, Y. (2017). Type III Intermediate Filaments Desmin, Glial Fibrillary Acidic Protein (GFAP), Vimentin, and Peripherin. Cold Spring Harbor Perspectives in Biology. https://doi.org/10.1101/cshperspect.a021642

3. Potokar, M., Morita, M., Wiche, G., & Jorgacevski, J. (2020). The Diversity of Intermediate Filaments in Astrocytes. Cells. https://doi.org/10.3390/cells9071604

4. Viedma-Poyatos, a., Pajares, M. A., & Perez-Sala, D. (2020). Type III intermediate filaments as targets and effectors of electrophiles and oxidants. Redox Biology. https://doi.org/10.1016/j.redox.2020.101582

Long Name

Glial Fibrillary Acidic Protein

Alternate Names

ALXDRD, FLJ45472, GFAP, GFAP astrocytes, glial fibrillary acidic protein

Gene Symbol

GFAP

Additional GFAP Products

Product Documents for GFAP Antibody (CL2713) - Azide and BSA Free

Product Datasheets

Download Product Datasheets

COA

SDS

Product Specific Notices for GFAP Antibody (CL2713) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Citations
Reviews